Study S000278

A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Italy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05230615
Acronym: PIONEER REAL
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 458
Start: 2022-04-01
Primary completion: 2023-10-31
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Oral semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1240-3945

Registered primary outcomes

Change in HbA1c (Glycated haemoglobin) [From baseline (week 0) to End of Study visit (V3) (week 34-44)]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006636	Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies. Rudofsky G, Diabetes therapy : research, treatment and education of diabetes and related disorders	2025	Nonrandomized study	PMID 39535683 DOI	cites ClinicalTrials.gov:NCT05230615; registry reference DERIVED:39535683
R0017787	PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes. Manti R, Diabetes therapy : research, treatment and education of diabetes and related disorders	2025	Nonrandomized study	PMID 40128506 DOI	cites ClinicalTrials.gov:NCT05230615; registry reference DERIVED:40128506